REGENERON PHARMACEUTICALS, INC. (REGN) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $59.2M sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $945.53 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.
Southeastern Asset Management · Sound Shore · Dodge & Cox Funds — 3 tracked funds hold REGN. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 93 sales ($59.2M). Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Southeastern Asset Management | 4.95% | 152,322 | ADDED (+16.6%) Q3 filed Nov 16 |
| Sound Shore | 2.44% | 126,994 | TRIMMED (-15.9%) Q3 filed Nov 6 |
| Dodge & Cox Funds | 1.59% | 4,871,137 | ADDED (+9.3%) Q3 filed Nov 13 |
| OrbiMed Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +53.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,331 of 8,857 filers |
| Long-only filers among them | 1,327 |
| Change vs 2026 Q1 | -46 net · 1,128 entered · 1,174 exited |
| Shares reported, all filers | 90,228,293 |
| Reported value, all filers | $56.5B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $14.3B |
| Net income · FY2025 | $4.5B |
| Total assets · FY2025 | $40.6B |
| Shares outstanding | 104,600,000 |
| Market cap (at latest close) | $98.9B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 2,134,934 |
| Share of shares outstanding | 2.04% |
| Days to cover | 3.18 |
Shares short at recent settlements — Jul 31, 2026: 3.4M · Aug 14, 2026: 2.4M · Aug 31, 2026: 2.6M · Sep 15, 2026: 2.5M · Sep 30, 2026: 2.2M · Oct 15, 2026: 2.1M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 1K · Aug 14, 2026: 60 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 93 sales by 9 insiders ($59.2M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 93 | $949.69 | $88.3K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 74 | $950.61 | $70.3K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 298 | $951.75 | $283.6K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 220 | $952.75 | $209.6K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 671 | $953.69 | $639.9K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 313 | $954.45 | $298.7K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 313 | $955.48 | $299.1K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 346 | $956.70 | $331.0K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 202 | $957.53 | $193.4K | SEC filing |
| Nov 17, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 244 | $958.27 | $233.8K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | McCourt Marion | Officer | 1,131 | $969.3K | Sep 3, 2026 | SEC filing |
| Sep 2, 2026 | McCourt Marion | Officer | 1,215 | $1.0M | Sep 2, 2026 | SEC filing |
| Sep 2, 2026 | Guarini Kathryn | Director | 400 | $340.0K | Sep 2, 2026 | SEC filing |
| Aug 10, 2026 | Zoghbi Huda Y | Director | 800 | $640.0K | Aug 10, 2026 | SEC filing |
| Aug 10, 2026 | Guarini Kathryn | Board member | 400 | $320.0K | Aug 10, 2026 | SEC filing |
| Jul 2, 2026 | Arthur F. Ryan | Director | 400 | $249.9K | Jul 2, 2026 | SEC filing |
| Feb 19, 2026 | Zoghbi Huda Y | Director | 1,638 | $1.3M | Feb 19, 2026 | SEC filing |
| Feb 9, 2026 | Pitofsky Jason | Officer | 2,036 | $1.6M | Feb 9, 2026 | SEC filing |
| Feb 9, 2026 | Arthur F. Ryan | Director | 400 | $314.2K | Feb 9, 2026 | SEC filing |
| Jan 7, 2026 | Bassler Bonnie L | Director | 1,500 | $1.2M | Jan 7, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 7,660,810 | 7.4% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Aug 6, 2025 | FMR LLC | SC 13G/A | 3,359,562.56 | 3.2% | Jun 30, 2025 | SEC filing |
| Jun 5, 2025 | JPMORGAN CHASE & CO. | SC 13G/A | 4,742,611 | 4.4% | May 30, 2025 | SEC filing |
| Apr 22, 2025 | JPMORGAN CHASE & CO. | SC 13G/A | 5,546,434 | 5.1% | Mar 31, 2025 | SEC filing |
| Feb 12, 2025 | FMR LLC | SC 13G/A | 8,188,770.17 | 7.6% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 1 sale).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Cisneros, Gilbert | House | D | 0 | 1 | May 15, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 190 Lobbying Disclosure Act filings named this company as client, 2012–2026; most common issues: Health Issues (129), Medicare/Medicaid (40), Budget/Appropriations (35).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Graham — Sound finances and a long run of profits
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 14.4% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 22.5% · Latest net income: $4.5B
· Graham — Current ratio: 4.13 · Straight profitable years: 14 · Debt ratio: 0.30 · Latest net income: $4.5B
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.09 · Operating cash flow: $5.0B · Net income: $4.5B
· Shareholder Yield — Shareholder yield: 4.3% · of which dividends: 0.4% · of which buybacks: 3.9%
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q3, ranked #29 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 2 | 0.0% | -11.3% | +1.9% | -13.2% |
| Share count tripled (3x) | 1 | 0.0% | -2.8% | +5.7% | -8.5% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold REGN — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Oct 30, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 6, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 8.01 Other Events | SEC filing |
| Sep 30, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on REGN
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.